You are here

Allergan

Allergan’s intravitreal implant wins approval in China

Drug Delivery Business News

Mon, 10/30/17 - 09:54 am

intravitreal implants

retinal vein occlusion

What to expect from the rest of pharma's earnings

BioPharma Dive

Mon, 10/30/17 - 09:52 am

Allergan: Is Linzess 'Restasis 2.0'?

NY Shock Exchange

Mon, 10/23/17 - 09:42 am

Ironwood Pharmaceuticals

Teva Pharmaceutical

Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent fight?

Endpoints

Sat, 10/21/17 - 09:44 pm

Allergan's stock-price struggles sure to trigger breakup questions: analyst

Fierce Pharma

Fri, 10/20/17 - 08:40 am

Court Finds Restasis Patents Invalid, Raises Concerns About Allergan, Mohawk Tribe Agreement

RAPS.org

Mon, 10/16/17 - 09:47 pm

'Sham' or legit? Texas judge set to weigh in on Allergan's tribal patent deal

Fierce Pharma

Mon, 10/16/17 - 12:53 pm

Allergan settles Restasis patent challenge after moving patents to Native American tribe

Drug Delivery Business News

Fri, 10/13/17 - 11:55 am

Ten big lobbying groups turn their guns on Allergan’s controversial patent gambit

Endpoints

Wed, 10/11/17 - 11:22 am

Allergan's Forest Labs to pay $4 million to settle discrimination charges by former sales reps

Reuters

Tue, 10/10/17 - 12:33 pm

gender discrimination

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

Endpoints

Fri, 10/6/17 - 09:44 am

3 Big Pharma Stocks Set to Succeed

Motley Fool

Thu, 10/5/17 - 09:36 am

Allergan moneymaker Botox grabs another cosmetic approval, this time in forehead lines

Fierce Pharma

Wed, 10/4/17 - 11:21 am

Allergan defends Restasis deal by calling for review of patent challenge process

Fierce Pharma

Tue, 10/3/17 - 11:59 am

Allergan’s tribal treaty in Restasis patent fight triggers a Congressional dispute

Endpoints

Thu, 09/28/17 - 09:37 am

Allergan: $2 Billion Share Buybacks Confirm Growth Is Dead

Seeking Alpha

Tue, 09/26/17 - 10:01 am

share repurchase

Allergan hit with FDA refusal to file letter

BioPharma Dive

Mon, 09/25/17 - 07:26 pm

refuse to file letters

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

Endpoints

Fri, 09/22/17 - 11:16 am

Apple Likes the Patent ‘Death Squad.’ Allergan Pays to Avoid It

Bloomberg

Wed, 09/20/17 - 09:14 am

Pages